Fig. 1

Molecular typing and treatment of breast cancer. The current molecular typing of breast cancer is mainly based on the surface receptors of the breast cancer cell membrane, which is mainly divided into luminal type (A), HER2 type (B), and Triple-negative type (C). At present, due to the expression of hormone receptors on the membrane surface, anti-hormone therapy (AI, TAM, CDK4/6i) is indicated for luminal breast cancer. The primary treatment of HER2 breast cancer is targeted anti-HER2 monoclonal antibody therapy (HER2-TKI, HER2-ADC, HER2 inhibitor). Triple-negative breast cancer can also be divided into six categories (BL1, BL2, IM, LAR, M, MSL, MSL) according to the different activation characteristics of intracellular signaling pathways. Chemotherapy is the main treatment choice for triple-negative breast cancer. However, with the deepening of research, some new anti-tumor drugs (PI3K inhibitors, PD-1 inhibitors, Trop2-ADC, anti-angiogenic drugs) also show the dawn in the clinical treatment of triple-negative breast cancer